Methods to predict and lower the risk of prostate cancer

Barbara Ercole, Dipen J. Parekh

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5α-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.

Original languageEnglish (US)
Pages (from-to)742-748
Number of pages7
JournalTheScientificWorldJournal
Volume11
DOIs
StatePublished - Apr 5 2011

    Fingerprint

Keywords

  • Chemoprevention
  • Dutasteride
  • Finasteride
  • PCPT risk calculator
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Medicine(all)

Cite this